An Updated Overview of Nanostructured Silver as a Novel Class of Biomedical Agent

In vitro and in vivo antibacterial activity of silver nanoparticles (AgNPs) against pathogenic bacteria has been demonstrated. Gram (+) and Gram (-) bacteria, including multidrug-resistant species, are susceptible to AgNPs' antibacterial effects. AgNPs have several concurrent mechanisms of action, and they work effectively with other antibacterial agents, such as antibiotics or chemical compounds, against infections like Esecheria coli and Staphylococcus aureus. Due to their unique characteristics, silver nanoparticles are perfect for use in healthcare and biomedical products where they can successfully treat or prevent infections. AgNPsʹ demonstrated genuine properties and significant potential for the development and improvement of novel antimicrobial agents, drug-delivery formulations, identification, detection, and diagnosis platforms, biomaterial and medical device coverings, tissue restoration and regeneration materials, complex healthcare condition schemes and strategies, and performance-enhanced therapeutic alternatives. The purpose of this review was to give a comprehensive discussion of the present state of the art in using the most relevant types of silver nanoparticles as antibacterial agents. This review aims to identify factors influencing the antibacterial impacts of silver nanoparticles and to highlight the benefits of using AgNPs as new antibacterial agents in addition to antibiotics, which will decrease the dosage necessary and avoid secondary effects combined with both. This is due to the need for new, effective, and efficient antibacterial agents.